The International Aspirin Foundation has today announced that Dr Andrew Chan will become Chair of its Scientific Advisory Board. Dr Chan succeeds Professor Carlo Patrono who will retire from the role, having led the Board since 2017.Dr Chan is Chief of the Clinical and Translational Epidemiology Unit and Vice Chair of the Division of Gastroenterology at Massachusetts General Hospital, Boston, USA and Co-leader, Cancer Epidemiology Program at the Dana-Farber/Harvard Cancer Center, Boston. An active member of The Foundation’s Scientific Advisory Board for eight years, his scientific interests include the role of aspirin in the prevention of colorectal cancer and other cancers, and he has been recognised with many awards including from the National Cancer Institute and the American Association for Cancer Research. He said: “I feel very privileged to take on this role and look forward to further developing The Foundation in exploring aspirin’s role in disease prevention and treatment for the global improvement of human health and well-being.” He highlights the need for continued research on the appropriate use of aspirin and dissemination of results to providers and patients. Pippa Hutchison, Executive Director of the International Aspirin Foundation (IAF) said: “We are delighted that Andrew has accepted this position and are also indebted to Carlo for all his hard work during his time as Chair. In recognition of his devotion to aspirin and The Foundation, Carlo has been awarded Honorary Fellowship of the IAF”
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?